NURIX THERAPEUTICS, INC. Total Liabilities and Equity
NURIX THERAPEUTICS, INC. (NRIX) had Total Liabilities and Equity of $535.54 million as of 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Balance Sheet
us-gaap:LiabilitiesAndStockholdersEquity · last filed 2026-07-09
- 2026-05-31: Liabilities and Equity $535.54M.
- 2026-02-28: Liabilities and Equity $636.13M.
- 2025-11-30: Liabilities and Equity $688.13M.
- 2025-08-31: Liabilities and Equity $522.47M.
| Period end | Liabilities and Equity |
|---|---|
| 2026-05-31 | $535.54M 10-Q · filed 2026-07-09 |
| 2026-02-28 | $636.13M 10-Q · filed 2026-04-08 |
| 2025-11-30 | $688.13M 10-Q · filed 2026-07-09 |
| 2025-08-31 | $522.47M 10-Q · filed 2025-10-09 |
| 2025-05-31 | $591.55M 10-Q · filed 2025-07-09 |
| 2025-02-28 | $615.04M 10-Q · filed 2025-04-08 |
| 2024-11-30 | $669.34M 10-K · filed 2026-01-28 |
| 2024-08-31 | $513.60M 10-Q · filed 2024-10-11 |
| 2024-05-31 | $511.03M 10-Q · filed 2024-07-11 |
| 2024-02-29 | $312.67M 10-Q · filed 2024-04-10 |
| 2023-11-30 | $355.60M 10-K · filed 2025-01-28 |
| 2023-08-31 | $308.19M 10-Q · filed 2023-10-12 |
| 2023-05-31 | $350.62M 10-Q · filed 2023-07-13 |
| 2023-02-28 | $370.15M 10-Q · filed 2023-04-13 |
| 2022-11-30 | $416.76M 10-K · filed 2024-02-15 |
| 2022-08-31 | $459.34M 10-Q · filed 2022-10-06 |
| 2022-05-31 | $394.31M 10-Q · filed 2022-07-07 |
| 2022-02-28 | $437.72M 10-Q · filed 2022-04-08 |
| 2021-11-30 | $476.77M 10-K · filed 2023-02-09 |
| 2021-08-31 | $493.07M 10-Q · filed 2021-10-14 |
| 2021-05-31 | $517.98M 10-Q · filed 2021-07-13 |
| 2021-02-28 | $396.66M 10-Q · filed 2021-04-13 |
| 2020-11-30 | $396.34M 10-K · filed 2022-01-28 |
| 2020-08-31 | $411.87M 10-Q · filed 2020-10-14 |
| 2019-11-30 | $44.05M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |